Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2009, for Isis Pharmaceuticals, Inc. (now Ionis Pharmaceuticals). The company is a biopharmaceutical firm focused on antisense technology and microRNA therapeutics. A significant event during this period was the completion of the sale of its subsidiary, Ibis Biosciences, Inc., to Abbott Molecular Inc. (AMI) on January 6, 2009, which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenue | $31.6 million | $18.4 million |
| Net Income (Loss) | $170.9 million | $(6.7) million |
| Net Income from Continuing Ops | $(0.8) million | $(6.1) million |
| Net Income from Discontinued Ops | $171.7 million | $(0.6) million |
| Cash and Cash Equivalents | $254.1 million | $271.9 million |
| Short-term Investments | $398.2 million | N/A (Not separately listed in Q1 2008 summary) |
| Total Debt Obligations | $134.0 million | $130.0 million |
| Working Capital | $527.2 million | $393.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 72% to $31.6 million, driven primarily by higher amortization of upfront payments from the strategic alliance with Genzyme and revenue from the Regulus Therapeutics collaboration with GSK.
- Discontinued Operations: The company recorded a net gain of $171.8 million from the sale of Ibis Biosciences, compared to a loss of $0.6 million in the prior year. This gain includes a $202.5 million pre-tax gain less $30.7 million in income taxes.
- Operating Expenses: Total operating expenses rose to $32.2 million from $24.6 million, attributed to expanded clinical development programs (specifically mipomersen) and increased costs for Regulus Therapeutics.
- Accounting Changes: The company adopted FSP 14-1 regarding convertible debt, resulting in a retrospective adjustment that increased interest expense by $1.7 million for Q1 2009 and reduced the carrying value of convertible notes.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur additional operating losses over the next several years as it continues to fund clinical trials. The company anticipates modest increases in R&D expenses for the remainder of 2009.
- Tax Position: Despite a net loss from continuing operations, the company expects a substantial taxable income for 2009 due to the Ibis sale and Genzyme upfront payments. Estimated annual tax expense for 2009 is $20 to $25 million.
- Key Risks:
- Regulatory Approval: Success depends on FDA approval for lead drug mipomersen; delays or failures in clinical trials could materially harm the business.
- Partner Dependence: Revenue relies heavily on a small number of partners (Genzyme, OMJP, BMS). Termination of these agreements could halt development.
- Liquidity: While cash and investments total $652.2 million, the company may require additional funding if commercialization goals are not met.
- Recent Developments: In April 2009, the company entered a new collaboration with Alnylam regarding single-stranded RNAi (ssRNAi) technology, receiving an $11 million upfront fee.
Investor Verification Checklist
- Verify the sustainability of revenue streams from the Genzyme collaboration and the amortization schedule of the $100 million stock premium and $175 million license fee.
- Confirm the status and timeline of the Phase 3 clinical trials for mipomersen, particularly the regulatory strategy for European and U.S. approval.
- Review the terms of the earn-out agreement with AMI regarding future Ibis Biosciences sales.
- Assess the impact of the new FSP 14-1 accounting standard on future interest expense and debt valuation.
- Monitor the progress of the Regulus Therapeutics joint venture and its Series A financing.